Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1974 2
1975 1
1976 2
1977 3
1978 1
1979 2
1980 1
1981 4
1982 2
1984 1
1985 2
1987 1
1988 2
1989 1
1990 2
1991 3
1993 4
1994 4
1995 3
1996 2
1997 3
1998 4
1999 5
2000 10
2001 12
2002 16
2003 11
2004 10
2005 25
2006 31
2007 59
2008 57
2009 51
2010 80
2011 63
2012 79
2013 97
2014 133
2015 140
2016 130
2017 99
2018 102
2019 125
2020 108
2021 123
2022 86
2023 95
2024 98
2025 75

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,715 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Kang YK, et al. Among authors: oh sy. Lancet Oncol. 2022 Feb;23(2):234-247. doi: 10.1016/S1470-2045(21)00692-6. Epub 2022 Jan 11. Lancet Oncol. 2022. PMID: 35030335 Clinical Trial.
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.
Lim SM, Schalm SS, Lee EJ, Park S, Conti C, Millet YA, Woessner R, Zhang Z, Tavera-Mendoza LE, Stevison F, Albayya F, Dineen TA, Hsieh J, Oh SY, Zalutskaya A, Rotow J, Goto K, Lee DH, Yun MR, Cho BC. Lim SM, et al. Among authors: oh sy. Ther Adv Med Oncol. 2024 Oct 21;16:17588359241280689. doi: 10.1177/17588359241280689. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39444426 Free PMC article.
Editorial: Insights in neuro-otology: 2021 and 2022.
Strupp M, Straka H, Oh SY. Strupp M, et al. Among authors: oh sy. Front Neurol. 2022 Dec 7;13:1104573. doi: 10.3389/fneur.2022.1104573. eCollection 2022. Front Neurol. 2022. PMID: 36570457 Free PMC article. No abstract available.
Evaluating Rituximab Failure Rates in Neuromyelitis Optica Spectrum Disorder: A Nationwide Real-World Study From South Korea.
Kim SH, Min JH, Kim SM, Lee EJ, Lim YM, Shin HY, Kwon YN, Sohn E, Kim S, Park MS, Nam TS, Yoon BA, Kim JK, Shin KJ, Kim YH, Seok JM, Bong JB, Kim S, Seok HY, Oh SY, Kwon O, Kim S, Lee S, Kim NH, Cho EB, Kang SY, Oh SI, Bae JS, Ahn SW, Kim KH, Kang YR, Ju W, Choo SH, Chung YH, Hyun JW, Kim HJ. Kim SH, et al. Among authors: oh sy. J Clin Neurol. 2025 Mar;21(2):131-136. doi: 10.3988/jcn.2024.0485. J Clin Neurol. 2025. PMID: 40065454 Free PMC article.
1,715 results